Abstract
Introduction
The novel coronavirus pneumonia that broke out in 2019 has become a global epidemic. According to the diagnosis and treatment plan issued in China and the existing clinical data, Shufeng Jiedu (SFJD) Capsule can be effectively used in the treatment of COVID-19 patients. This study aimed to explore its mechanism of action by network pharmacology and molecular docking technology.
Methods
The Chinese Medicine System Pharmacology Analysis Platform (TCMSP), a Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine (BATMAN-TCM), the Encyclopedia of Traditional Chinese Medicine (ETCM) and related literature records were used to search the composition and main active compounds of SFJD, and to screen out the targets of drug components. Disease-associated genes were obtained by the Human Gene Database (GeneCards), the Human Online Mendelian Inheritance Platform (OMIM) and the DisGeNET database, and the co-targeted genes/proteins as targets of both SFJD and COVID-19 were selected by the Comparative Toxicogenomics Database (CTD). Co-targeted genes/proteins were analyzed by STRING, the Database for Annotation, Visualization and Integrated Discovery (DAVID) and Reactome for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment, and predicted by AutoDock for their high-precision docking simulation. In addition, the therapeutic effect for SFJD treatment on COVID-19 was validated by the Chinese medicine anti-novel coronavirus pneumonia drug effect prediction and analysis platform (TCMCOVID).
Results
Screening resulted in 163 compounds and 463 targeted genes. The PPI core network contains 76 co-targeted proteins. The Reactome pathways were enriched in signaling by interleukins, immune system, etc. Finally, 6 key proteins of TNF, IL-10, IL-2, IL-6, STAT1 and CCL2 were selected and successfully docked with 4 active ingredients of quercetin, luteolin, wogonin and kaempferol.
Conclusion
SFJD may play a role in the prevention and treatment of COVID-19 through multiple active compounds acting on multiple targets and then multiple pathways.
Keywords: COVID-19, Traditional Chinese medicine, Network pharmacology, Shufeng Jiedu capsule, Mechanism
Abbreviations
- ACE2
Angiotensin-converting enzyme 2
- AKT1
RAC-alpha serine/threonine-protein kinase
- BCL2L1
Bcl-2-like protein 1
- BDKRB2
B2 bradykinin receptor
- CASP3/8
Caspase-3/8
- CCL2
C-C Motif Chemokine Ligand 2
- CSNK2B
Casein kinase II subunit beta
- COMT
Catechol O-methyltransferase
- COVID-19
Coronavirus disease 2019
- CTD
Comparative Toxicogenomics Database
- CXCL8
Interleukin-8
- CYP1A1
Cytochrome P450 1A1
- CYP3A4
Cytochrome P450 3A4
- EGFR
Epidermal growth factor receptor
- ESR1
Estrogen receptor
- ETCM
Encyclopedia of Traditional Chinese Medicine
- FOS
Proto-oncogene c-Fos
- FPR2
N-formyl peptide receptor 2
- GLA
Alpha-galactosidase A
- GO
Gene ontology
- GTEx
Genotype-Tissue Expression Portal database
- HMOX1
Heme oxygenase 1
- HSP90
Heat shock protein HSP 90
- IL-2/6/10
interleukin-2/6/10
- JUN
Transcription factor AP-1
- MAPK
Mitogen-activated protein kinase
- MPO
Myeloperoxidase
- ORA
Over-representation analysis
- PLAT
Tissue-type plasminogen activator
- PPARG
Peroxisome proliferator-activated receptor gamma
- PPI
Proteins to protein interaction
- PRKACA
cAMP-dependent protein kinase catalytic subunit alpha
- PTGS2
Prostaglandin G/H synthase 2
- RELA
Transcription factor p65
- SFJD
Shufeng Jiedu
- STAT1/3
Signal transducerand activator of transcription 1/3
- TCM
Traditional Chinese Medicine
- TCMCOVID
The Chinese medicine anti-new coronavirus pneumonia drug effect prediction and analysis platform
- TCMSP
The Chinese Medicine System Pharmacology Analysis Platform
- TNF
Tumor Necrosis Factor
- TP53
Cellular tumor antigen p53
- VEGFA
Vascular endothelial growth factor A
1. Introduction
Coronavirus disease 2019 (COVID-19) caused by a novel virus strain, 2019-nCoV/SARS-CoV-2 spread rapidly around the world in the first half of 2020 causing a global pandemic [1], and has posed a serious threat to global public health and economy [2]. COVID-19 is a respiratory illness. Traditional Chinese Medicine (TCM) plays a significant role in the treatment of respiratory diseases in China [3]. The research on antiviral TCM literature in the past 20 years suggests that the antiviral TCM is mainly based on clearing heat and detoxification [4]. SFJD capsule is a typical antibacterial and antiviral compound preparation used for this purpose.
As an ancient system of alternative medicine, TCM played an active role in the prevention and control of COVID-19 in China. It improved the clinical symptoms of patients, reduced the mortality rate, improved the recovery rate, and effectively relieved the operating pressure on the national medical system during a critical time [5]. TCM has its unique advantages for treatment based on syndrome differentiation [6]. TCM can provide more effective and personalized treatment via adjusting the specific medicine for each patient based on the different syndromes. TCM often has different effects on the distinct stages of diseases, contributing to the prevention, treatment and rehabilitation [7]. The analysis of Chinese medical sciences theory and clinical application of TCM shows that TCM contributes a systematic theoretical understanding about the pathological evolution and a positive clinical efficacy on novel coronavirus pneumonia [8]. As an indispensable part of TCM, Chinese patent medicines are highly valued and critically acclaimed in their campaign to contain and tackle the epidemic, they can achieve considerable effects for both suspected cases under medical observation period, and confirmed individuals with serious underlying diseases or critical conditions [9]. At present, there is a report that ranks the frequencies of Chinese Patent Medicine recommendations by guidelines and expert consensus for treatment of COVID-19 in China. Among them, the top 10 Chinese Patent Medicines include Shufeng Jiedu (SFJD) Capsule [10].
The Chinese national guideline summarised the opinions and frontline experience of medical experts across the country to provide by far the best management for COVID-19 [11]. According to "Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Seventh Edition)" in China, it is recommended to use Chinese patent medicine Shufeng Jiedu Capsules (granules) during the medical observation period when there are clinical manifestations of fatigue and fever. [12]. According to the clinical trial results of 200 ordinary COVID-19 patients in Wuhan Third Hospital from January 27, 2020 to March 5, 2020, it was found that the combined application of SFJD capsules with Western medicine could significantly improve ordinary COVID-19 patients with clinical symptoms such as cough, expectoration, fatigue, chest tightness and wheezing, improve the effectiveness of the main symptoms, regulate the expression of related peripheral blood inflammation indicators, promote the absorption of lung inflammation, and increase the cure rate [13]. According to the clinical trial results of 200 patients with mild novel coronavirus pneumonia in outpatient clinics of Wuhan Central Hospital from January 24 to January 30, 2020, SFJD capsule combined with Abidol in the treatment of mild novel coronavirus pneumonia can significantly improve the blood composition of patients, the percentage level of white blood cells and lymphocytes, make the chest CT infected foci obvious absorption [14]. According to the clinical trial results of 70 COVID-19 patients diagnosed and treated at the COVID-19 designated hospital Bozhou People's Hospital from January 31, 2020 to February 11, 2020, it was shown that the addition of SFJD capsule can shorten the time for patients to improve their clinical symptoms and the time for SARS-CoV-2 to become negative [15].
SFJD capsule evolved from "Detox Powder"9, and it is commonly used for clinical treatment of acute upper respiratory tract infection caused by wind-heat syndrome [16]. Modern pharmacological studies have shown that SFJD capsules have a relatively broad inhibitory effect on common fungi, viruses, bacteria, etc. [9], and have a broad-spectrum antiviral effect in vitro [17]. In addition, SFJD and antibiotic combination therapy can reduce the inflammatory response and improve prognosis for septic patients [18]. SFJD is an eight-herb prescription that Hu Zhang (Polygoni cuspidati Rhizoma et Radix) is the monarch-ingredient; Ban Lan Gen (Isatidis Radix) and Lian Qiao (Forsythiae Fructus) are adjutant-ingredients; Lu Gen (Phragmitis Rhizoma), Bai Jiang Cao (Patrinia scabiosifolia Herba), Ma Bian Cao(Verbenae Herba) and Chai Hu(Bupleuri Radix) are assistant-ingredients; Gan Cao(Glycyrrhizae Radix et Rhizoma) is the envoy-ingredient [9].
The TCM network pharmacology approach provides a new research paradigm for translating TCM from an experience-based medicine to an evidence-based medicine system. It was created to prioritize disease-associated genes, to predict the target profiles and pharmacological actions of herbal compounds, to reveal drug-gene-disease co-module associations, to screen synergistic multi-compounds from herbal formulae in a high-throughput manner, and to interpret the combinatorial rules and network regulation effects of herbal formulae [19]. Therefore, we used network pharmacology tools to study the molecular mechanism of SFJD against COVID-19, aiming to provide a theoretical basis for the clinical application of SFJD and more accurate and effective use in the treatment of clinical COVID-19 patients. As shown in Fig. 1 , to explore the molecular mechanism for SFJD against COVID-19, we tried to integrate the bioinformatics and network pharmacology tools [20] to predict the target genes and proteins and to analyze the interactions between SFJD ingredients with the targeted genes.
2. Methods
2.1. Meridian tropism and main active compounds analysis
ETCM (http://www.nrc.ac.cn:9090/ETCM/index.php/Home/Index/) is a comprehensive resource database of traditional Chinese medicine, which gathers information on herbal medicines, traditional Chinese medicine compounds, chemical components of traditional Chinese medicines, drug targets and related diseases. The herbal medicine contains information such as origin, medicinal taste, medicinal properties, meridian, indications, ingredients, and quality control standards. TCMSP (http://tcmspw.com/tcmsp.php) is a unique Chinese herbal medicine system pharmacology platform, which contains 499 herbal medicines and the compound components of each herbal medicine. It provides comprehensive evaluation data of human absorption, distribution, and metabolism (ADME) properties for each compound. It also provides targets of potentially active molecules and their disease information. BATMAN-TCM (http://bionet.ncpsb.org/batman-tcm/) is the first online bioinformatics analysis tool specifically designed for studying the molecular mechanisms of traditional Chinese medicine, and it can predict the potential target of each query of Chinese medicine components. Choosing the 8 herbs of TCM composed of SFJD as keywords, the ETCM was used to query the meridian and the TCMSP and BATMAN-TCM were used to search the main active compounds of 8 herbs.
2.2. Ingredients targeted genes and Disease-associated genes mining
TCMSP was used to mine the targeted genes information of the main active compounds obtained in 2.1. Ingredients targeted genes of SFJD were made the official name through Uniport (https://www.uniprot.org/). GeneCards (https://www.genecards.org/) is a comprehensive database that can analyze human genetic data. Its main functions include analyzing gene expression, functional pathways, protein-protein interactions, and the relationship between genes and diseases. The DisGeNET (http://www.disgenet.org/) database is one of the largest databases containing human diseases and related gene targets, including 17,549 genes and 24166 diseases. OMIM (http://www.ncbi.nlm.nih.gov/omim) is a database that records the genetic components of all known diseases and predicts their relationship with related genes in the human genome. As SFJD was used to treat symptoms such as fever and fatigue during the medical observation period of novel coronavirus pneumonia, "Novel coronavirus pneumonia", "COVID-19", "Fever" and "Fatigue" were used as keywords to mine disease-associated genes by GeneCards, DisGeNET and OMIM. Through the CTD (http://ctdbase.org/) for Venn analysis, the co-targeted genes were obtained.
2.3. PPI and GO analysis
With STRING (search tool for the retrival of interacting genes/proteins) (https://string-db.org), we analyzed the co-targeted proteins that are encoded by disease-associated genes that interact with SFJD ingredient-targeted genes to explore their relationship within a PPI network. DAVID (https://david.ncifcrf.gov/) is a biological information database that provides systematic and comprehensive biological function annotation information for large-scale gene or protein lists. Entered the above targets into DAVID, and selected the species as "homo sapiens", set the threshold value P≤0.05 for GO enrichment analysis, and used Graphpad software to draw the results into histograms.
2.4. Reactome pathways enrichment
The Reactome Knowledgebase (https://reactome.org) provides molecular details of pathways and reactions in human biology. Reactome Knowledgebase is a new tool for studying biological pathways at a holistic level, and it can simplify data search and research related to biological pathways. We used it to draw two pathways that co-targeted genes set enriched.
2.5. Classic anti-COVID-19 prescription validation
The Chinese medicine anti-novel coronavirus pneumonia drug effect prediction and analysis platform (TCMAntiCOVID-19 V1.0, http://tcmatcov.bbtcml.com/) can realize the rapid prediction and analysis of the potential drug effect of traditional Chinese medicine or prescriptions and provide a reference for the evaluation of drug efficacy [21]. It compares the changes of network topological characteristics before and after drug intervention, and uses the disturbance rate to evaluate the effect of drugs on disease. Based on the TCMATCOV platform, SFJD was calculated and predicted to have a high disturbance score and to account for a high proportion of the classic anti-COVID-19 prescriptions used by clinicians. We built a component-drug target-disease protein interaction network on the TCMATCOV platform.
2.6. Molecular docking
Combining the targets analyzed by the PPI and the TCMATCOV platform, the overlapping targets were selected as the core target genes, and then the compound with high frequency corresponding to the core target genes were used as the core compounds. Selected core compounds and download the sdf structure of the compound from the PubChem (https://pubchem.ncbi.nlm.nih.gov/) database. The files were imported into AutoDock software to add charge and display rotatable keys and then saved in pdbqt format. The protein crystal structures corresponding to the core target genes were downloaded from the PDB database, imported into PyMOL software to remove water molecules and hetero molecules, imported into AutoDock software to add hydrogen atoms and charge operations, saved to pdbqt format. The above core compounds were used as ligands, and the proteins corresponding to the core target genes were used as receptors for molecular docking. From the 50 results, the one with the largest binding energy and the largest number of hydrogen bonds was selected as the final result. The results were analyzed and interpreted by PyMOL software.
3. Results
3.1. Meridian tropism and main active compounds analysis
The results of ETCM and literature search are shown in Table 1 . The seven other herbs except for Gan Cao are all categorized as bitter cold, mainly in the lung, stomach and liver meridians.
Table 1.
Herb name | Herb Property | Herb Flavor | Herb Meridian Tropism |
---|---|---|---|
Hu Zhang (Polygoni cuspidati Rhizoma et Radix) |
Mildly cold |
Mildly bitter |
Gallbladder meridian, Lung meridian, Liver meridian |
Lian Qiao (Forsythiae Fructus) |
Mildly cold |
Bitter |
Lung meridian, Small intestine meridian, Heart meridian |
Ban Lan Gen (Isatidis Radix) |
Cold |
Bitter |
Stomach meridian, Heart meridian |
Chai Hu (Bupleuri Radix) |
Mildly cold |
Bitter, Pungent |
Gallbladder meridian, Lung meridian, Liver meridian |
Bai Jiang Cao (Patrinia scabiosifolia Herba) |
Mildly cold | Bitter, Pungent |
Stomach meridian, Large intestine meridian, Liver meridian |
Ma Bian Cao (Verbenae Herba) |
Cold | Bitter, Pungent |
Liver meridian, Spleen meridian |
Lu Gen (Phragmitis Rhizoma) |
Cold |
Sweet |
Bladder meridian, Lung meridian, Stomach meridian |
Gan Cao (Glycyrrhizae Radix et Rhizoma) |
Even |
Sweet |
Lung meridian, Spleen meridian, Stomach meridian, Heart meridian |
A total of 163 active ingredients of SFJD were retrieved through the TCMSP and BATMAN-TCM. In addition to Gan Cao, 43 compounds were excavated with oral bioavailability (OB) ≥50% and drug-likeness (DL) ≥0.18 as parameters. The remaining 7 herbs were excavated with OB ≥30% and DL ≥0.18 as parameters. There are 10 effective compounds in Hu Zhang, 26 in Lian Qiao, 42 in Ban Lan Gen, 17 in Chai Hu, 12 in Bai Jiang Cao, 12 in Ma Bian Cao, and 1 in Lu Gen. Sorted by DL value, Table 2 showed the top 20 active ingredients (more details showed in supplement material 1).
Table 2.
Herbs | Mol ID | Molecule Name | CAS | OB (%) | DL |
---|---|---|---|---|---|
Ban Lan Gen | MOL001810 | 6-(3-oxoindolin-2-ylidene)indolo[2,1-b]quinazolin-12-one | 97457-31-3 | 45.28 | 0.89 |
Lian Qiao | MOL000791 | bicuculline | 485-49-4 | 69.67 | 0.88 |
Gan Cao | MOL005018 | Xambioona | N/A | 54.85 | 0.87 |
Lian Qiao | MOL003305 | PHILLYRIN | 487-41-2 | 36.4 | 0.86 |
Lian Qiao | MOL003365 | Lactucasterol | N/A | 40.99 | 0.85 |
Lian Qiao | MOL000522 | arctiin | 20362-31-6 | 34.45 | 0.84 |
Ma Bian Cao | MOL008752 | Dihydroverticillatine | N/A | 42.69 | 0.84 |
Ban Lan Gen | MOL001806 | Stigmasta-5,22-diene-3beta,7beta-diol | N/A | 42.56 | 0.83 |
Ban Lan Gen | MOL001804 | Stigmasta-5,22-diene-3beta,7alpha-diol | N/A | 43.04 | 0.82 |
Lian Qiao | MOL003281 | 20(S)-dammar-24-ene-3β,20-diol-3-acetate | N/A | 40.23 | 0.82 |
Lian Qiao | MOL003315 | 3beta-Acetyl-20,25-epoxydammarane-24alpha-ol | N/A | 33.07 | 0.79 |
Lian Qiao | MOL000211 | Mairin | 472-15-1 | 55.38 | 0.78 |
Lian Qiao | MOL000211 | Betulinic Acid | 472-15-1 | 55.38 | 0.78 |
Gan Cao | MOL000211 | Mairin | 472-15-1 | 55.38 | 0.78 |
Gan Cao | MOL005001 | Gancaonin H | 126716-35-6 | 50.1 | 0.78 |
Ban Lan Gen | MOL001755 | 24-Ethylcholest-4-en-3-one | 67392-96-5 | 36.08 | 0.76 |
Ban Lan Gen | MOL000449 | Stigmasterol | 83-48-7 | 43.83 | 0.76 |
Chai Hu | MOL000449 | Stigmasterol | 83-48-7 | 43.83 | 0.76 |
Chai Hu | MOL004718 | α-spinasterol | 481-18-5 | 42.98 | 0.76 |
Bai Jiang Cao | MOL000449 | Stigmasterol | 83-48-7 | 43.83 | 0.76 |
3.2. Disease-associated genes targeted by SFJD
According to GeneCards, OMIM and DisGeNET search, 429 "Novel coronavirus pneumonia" target genes, 324 "COVID-19" target genes, 7385 "Fever" target genes, and 7384 "Fatigue" target genes were obtained. 383 disease-associated genes were obtained by Venn analysis, as shown in Fig. 2 (A). Through TCMSP and BATMAN-TCM (score≥20; P<0.05) mining, 463 ingredients targeted genes of SFJD were obtained, which were subjected to Venn analysis with disease-associated genes to obtain 76 co-targeted genes of SFJD for preventing COVID-19, as shown in FIG. 2 (B).
3.3. The PPI networks of SFJD targeted proteins
Using STRING, we analyzed the interactions of 76 proteins that are disease-associated genes interaction with SFJD ingredient-targeted genes on the condition of highest confidence of 0.900, and the multiple PPI enrichment were obvious (P <1.0e−16). As shown in Fig. 3 , the circular nodes represent the genes, and the straight line between the nodes represents the connection between the two genes, The darker the line, the stronger the correlation. We abandoned the above proteins with no effect relationship, imported the results into the Cytoscape software as a TSV format file for target relationship mining, and arranged them in the order of Degree, Closeness, Betweenness and Topological Coefficient, and selected the targets with a Degree greater than or equal to 10 as the " important targets" ", the results were shown in Table 3 (more details showed in supplement material 3).
Table 3.
Targets | Degree | Topological Coefficient | Betweenness Centrality | Closeness Centrality |
---|---|---|---|---|
RELA | 24 | 0.23065476 | 0.09948818 | 0.544 |
MAPK1 | 24 | 0.19791667 | 0.12555263 | 0.53968254 |
IL6 | 23 | 0.23510467 | 0.11059687 | 0.52713178 |
MAPK3 | 23 | 0.21661491 | 0.08636058 | 0.53543307 |
TNF | 23 | 0.21510297 | 0.11857879 | 0.544 |
TP53 | 19 | 0.22105263 | 0.10271104 | 0.4822695 |
MAPK8 | 17 | 0.27566321 | 0.0445486 | 0.48920863 |
MAPK14 | 17 | 0.25860155 | 0.06081331 | 0.5 |
IL1B | 16 | 0.29211957 | 0.0161661 | 0.46896552 |
IL2 | 15 | 0.32533333 | 0.01679801 | 0.47887324 |
NFKB1 | 15 | 0.30068027 | 0.02367776 | 0.47552448 |
FOS | 15 | 0.28148148 | 0.03306335 | 0.49635036 |
IL10 | 13 | 0.33679834 | 0.00804039 | 0.42236025 |
IL4 | 13 | 0.32915921 | 0.01284505 | 0.45033113 |
STAT1 | 12 | 0.29411765 | 0.02445102 | 0.47552448 |
IFNG | 11 | 0.35909091 | 0.01944479 | 0.425 |
CCL2 | 11 | 0.35698448 | 0.00735614 | 0.43312102 |
INS | 11 | 0.17748918 | 0.15055889 | 0.45637584 |
IL13 | 10 | 0.4 | 0.00565501 | 0.41212121 |
LCK | 10 | 0.375 | 0.00134214 | 0.44444444 |
CASP8 | 10 | 0.35102041 | 0.01572466 | 0.45945946 |
BCL2L1 | 10 | 0.34324324 | 0.00764597 | 0.40718563 |
EGFR | 10 | 0.27454545 | 0.03172251 | 0.4822695 |
We used DAVID to perform GO enrichment analysis on the above 76 proteins. Taking "Homo sapiens, p≤0.05" as the screening condition, the top 20 were drawn as histograms, as shown in Fig. 4 (more details showed in supplement material 4). Among them, biological processes involve inflammatory response, positive regulation of transcription from RNA polymerase II promoter, immune response, etc.; molecular functions include ATP binding, cytokine activity and metal ion binding are the most significant; among the cellular components, extracellular space, extracellular exosome and nucleus are enriched more.
3.4. Reactome pathways enrichment
We used the Reactome knowledgebase as the enrichment tool with co-targeted genes for Reactome pathways enrichment. As shown in Table 4 (more details showed in supplement material 5), the results indicated that the pathways were enriched in interleukin-10 signaling, interleukin-4 and interleukin-13 signaling, signaling by interleukins, cytokine signaling in the immune system, the immune system and other pathways. These pathways are important in storms caused by COVID-19. With the Reactome knowledgebase, we draw the simulation diagrams for SFJD treatment during SARS-CoV-2 infection in the immune system (Fig. 5 A), cytokine signaling in immune system (HSA-1280215, Fig. 5 B), signaling by interleukins (R-HSA-449147, Fig. 5 C) which showed the possible targets for SFJD and SARS-CoV-2 with hit gene numbers and false discovery rate (FDR) scores. These simulation diagrams have vividly illustrated the mechanism of SFJD treatment for COVID-19.
Table 4.
Pathway identifier | Pathway name | Entities found | Entities total | Entities ratio | Entities pValue | Entities FDR | Reactions found | Reactions total | Reactions ratio |
---|---|---|---|---|---|---|---|---|---|
R-HSA-6783783 | Interleukin-10 signaling | 22 | 86 | 0.005861 | 1.11E-16 | 2.04E-14 | 13 | 15 | 0.001157 |
R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 36 | 211 | 0.01438 | 1.11E-16 | 2.04E-14 | 35 | 46 | 0.003549 |
R-HSA-449147 | Signaling by Interleukins | 62 | 639 | 0.043549 | 1.11E-16 | 2.04E-14 | 171 | 490 | 0.037803 |
R-HSA-1280215 | Cytokine Signaling in Immune system | 73 | 1312 | 0.089416 | 1.11E-16 | 2.04E-14 | 239 | 735 | 0.056704 |
R-HSA-168256 | Immune System | 84 | 2869 | 0.195529 | 1.11E-16 | 2.04E-14 | 330 | 1634 | 0.126061 |
R-HSA-109606 | Intrinsic Pathway for Apoptosis | 12 | 61 | 0.004157 | 4.88E-13 | 7.52E-11 | 27 | 62 | 0.004783 |
R-HSA-5660668 | CLEC7A/inflammasome pathway | 6 | 8 | 5.45E-04 | 1.48E-10 | 1.95E-08 | 4 | 4 | 3.09E-04 |
R-HSA-447115 | Interleukin-12 family signaling | 11 | 96 | 0.006543 | 1.34E-09 | 1.47E-07 | 22 | 114 | 0.008795 |
R-HSA-8950505 | Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 10 | 73 | 0.004975 | 1.44E-09 | 1.47E-07 | 5 | 36 | 0.002777 |
R-HSA-2559583 | Cellular Senescence | 14 | 200 | 0.01363 | 3.80E-09 | 3.50E-07 | 39 | 90 | 0.006943 |
3.5. Prediction of SFJD−COVID-19 disease treatment by TCMATCOV
As shown in Fig. 6 , we built a component-drug target-disease protein interaction network on the TCMATCOV platform, which included the component-drug target relationship (from BATMAN-TCM, with a confidence score of 20), and protein interactions between drug targets and disease proteins relationship (from STRING with a confidence score of 0.5). The data showed that the SFJD therapeutic effect on COVID-19 was very close to the positive control (HSZF), which had been reported to be useful in clinical. We also validated the herbs in SFJD prescription, and the data showed in Table 5. TCMATCOV is a COVID-19 severe disease network based on SARS simulation. We used it to predict 126 anti-COVID-19 target genes. However, we used GeneGards, DisGeNET, OMIM and other databases to select 76 co-targeted genes based on the clinical symptoms of fever and fatigue during the medical observation period. As shown in Table 6 , the targets predicted by these two methods were subjected to Venn analysis, and the eight genes obtained were used as core target genes for the prevention and treatment of COVID-19, and the corresponding high-frequency compounds were used as core compounds.
Table 5.
TCM herbs | Sum score | Average Degree | Average shortest path | Degree centrality | Closeness centrality |
---|---|---|---|---|---|
Negative Control (BXTM) | 12.59 | -1.84 | 3.53 | -0.76 | -6.46 |
Positive Control (HSZF) | 20.85 | -4.09 | 9.01 | -1.12 | -6.63 |
SFJD | 20.84 | -4.05 | 9.28 | -1.19 | -6.33 |
Hu Zhang | 16.36 | -4.65 | 2.87 | -4.89 | -3.95 |
Lian Qiao | 8.79 | -2.10 | -0.21 | -0.45 | -6.45 |
Ban Lan Gen | 18.04 | -4.81 | 5.94 | -1.09 | -6.21 |
Chai Hu | 16.88 | -2.60 | 7.47 | -1.13 | -5.68 |
Table 6.
Core target genes | Gene description | Predicted ingredients | TCM Herbs |
---|---|---|---|
IL-10 | Interleukin 10 | Quercetin; Luteolin; |
Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; Hu Zhang, Chai Hu, Ma Bian Cao, Bai Jiang Cao |
TNF | Tumor Necrosis Factor | Quercetin; Luteolin; Kaempferol; Wogonin; Isovitexin; |
Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; Hu Zhang, Chai Hu, Ma Bian Cao, Bai Jiang Cao; Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; Lian Qiao; Bai Jiang Cao |
IL-6 | Interleukin 6 | Quercetin; Luteolin; Wogonin; |
Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; Hu Zhang, Chai Hu, Ma Bian Cao, Bai Jiang Cao; Lian Qiao |
IL-2 | Interleukin 2 | Quercetin; Luteolin; |
Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; Hu Zhang, Chai Hu, Ma Bian Cao, Bai Jiang Cao |
CCL2 | C-C Motif Chemokine Ligand 2 | Quercetin; Wogonin; |
Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; Lian Qiao |
STAT1 | Signal transducer and activator of transcription 1-alpha/beta | Quercetin; Kaempferol; |
Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
IFNG | Interferon gamma | Quercetin; Luteolin; |
Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; Hu Zhang, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
CXCL10 | C-X-C motif chemokine 10 | Quercetin; | Hu Zhang, Lian Qiao, Chai Hu, Ma Bian Cao, Bai Jiang Cao; |
3.6. Molecular docking verification of core compounds and core target genes
According to the binding energy and the number of hydrogen bonds, especially the greater the absolute value of the binding energy, the better the molecular docking result. The two proteins most related to the four core compounds were selected, as shown in Fig. 7 and Table 7 (original data showed in supplement material 7). Quercetin has the largest relationship with TNF and STAT1. Luteolin has the largest relationship with IL-2 and STAT1. Wogonin has the largest relationship with TNF and CCL2. Kaempferol has the largest relationship with IL-10 and IL-6. These results can prove that SFJD ingredients work with COVID-19 targeted proteins in molecular docking simulation.
Table 7.
Compounds | Target genes (ID) | Binding energy | The number of hydrogen bonds |
---|---|---|---|
Quercetin | TNF (5M2J) | -4.82 | 5 |
Quercetin | STAT1 (2KA6) | -4.6 | 2 |
Luteolin | IL2 (5LQB) | -5.2 | 4 |
Luteolin | STAT1 (2KA6) | -5.55 | 1 |
Wogonin | TNF (5M2J) | -4.9 | 1 |
Wogonin | CCL2 (4R8I) | -5.26 | 3 |
Kaempferol | IL10 (1LK3) | -5.48 | 4 |
Kaempferol | IL6 (5FUC) | -5.32 | 3 |
4. Discussion
Interleukin-6 (IL-6) plays an important role in cytokine release syndrome [22]. Some research has found that cytokines play an important role in the pathogenesis of COVID-19. Also, IL-6 seems more relevant in the evaluation of the condition of COVID-19 patients [23]. In addition to the core proteins such as IL-6, which are involved in molecular docking simulation, the T-helper 1 cytokines (IL1B, IFN-γ, IP10, and MCP1) increase in patients infected by SARS-COV-2 [24] and other co-targeted genes such as IFNG and MAPK are also involved. IFNG is generally considered to be an inflammatory cytokine that plays a key role in anti-tumor immunity. Studies have found that high levels of IFNG activate the JAK1-STAT1-caspase pathway and induce apoptosis in non-small cell lung cancer [25]. MAPK can regulate many important cell physiological/pathological processes such as cell growth, differentiation, stress adaptation to the environment, and inflammatory response [26]. Thus, combined with the enrichment analysis results of GO and Reactome pathway, cytokines and other molecules involved in immune response and inflammation are conceivable therapeutic targets for SFJD.
COVID-19 can spread quickly through respiratory tract droplets, close contact, and aerosols. In addition, there are reports that direct evidence of the active SARS-CoV-2 replication in the patient's rectum during the incubation period, which might explain SARS-CoV-2 fecal-oral transmission [27]. Clinical studies of patients with COVID-19 have shown that coronavirus can cause a variety of human diseases, including respiratory symptoms, gastrointestinal diseases [28], varying degrees of liver injury or liver dysfunction [29], thrombotic complications, myocardial dysfunction and arrhythmia, acute coronary syndromes, acute kidney injury, ocular symptoms, dermatologic complications [30] and so on.
Most of SFJD components are bitter cold herbs with the effect of clearing heat and detoxification, and mainly belong to the lung meridian, which plays an obvious therapeutic role on the syndrome of wind-heat syndrome of upper scorched lung. Amazingly, the therapeutic effect of each component of SFJD is not only limited to the lung, but also has a certain protective effect on the damage of other tissues and organs. The effective core compounds of SFJD such as quercetin, luteolin, wogonin, Kaempferol, etc. were screened through network pharmacology. They are mainly natural flavonoids, which exist in many natural medicinal materials and have various pharmacological activities. Quercetin can improve immune function via NF-κB signaling pathway triggered by TNF-α [31]. It has a protective effect against the liver tissues of rats [32] and colitis of mice [33]. Both in vivo and in vitro experiments have demonstrated that quercetin can alter cell cycle [34]. Highlights Quercetin ameliorates hypoxia-evoked apoptosis [35]. Luteolin has anti-inflammatory [36], anti-oxidation [37,38], protecting the kidneys [39] and other pharmacological effects. It can potently inhibit influenza virus replication in vitro [40]. Kaempferol has the effect of inhibiting cell proliferation and inducing apoptosis [41]. It can protect the liver against propacetamol-induced injury [42] and protect mice from liver failure [43]. Kaempferol showed attenuation in sepsis-induced acute lung injury in mice [44]. In addition, it has the effect of antitumor and cardioprotective [45]. Wogonin attenuated tubular damage, suppressed kidney inflammation and inhibited NF-κB activation in the injured kidney, thereby exhibiting the renoprotective effect [46] and it is a promising nephroprotective agent [47]. Pro-apoptosis effect of wogonin in vivo was verified in situ [48]. Wogonin exhibits a cytotoxic effect on lung cancer cells [49] and exerts potent anticancer effects on colorectal cancer cells [50]. Wogonin has documented a wide spectrum of anti-inflammatory and antitumor activities, including inhibiting regulatory T cells, regulating effector T cell functions, and mediating macrophage immunity [51]. In addition, wogonin possesses a potent anti-influenza activity mediated by regulation of AMPK activation [52]. The multiple protective effects of these active ingredients on other tissues and organs may be one of the reasons for SFJD to reduce the symptoms of COVID-19 patients. TCM is a combination of multiple components to play a therapeutic effect, in addition to these four core compounds, the remaining components also play a pivotal role.
Recently, there are many clinical applications of TCM in the treatment of COVID-19 and many scholars have also studied its mechanism through network pharmacology, as shown in Table 8. Through comparison, it is found that whether it is a single medicine or a prescription, TCM treats COVID-19 mostly by regulating inflammatory factors. Our research found that SFJD not only regulates inflammation, but also mainly participates in regulating the immune system to treat COVID-19.
Table 8.
TCM | Tools | Results | Ref |
---|---|---|---|
ShuFeng JieDu capsule | TCMSP; GeneCards; DAVID; R software |
Key targets: RELA, MAPK1, MAPK14, CASP3, CASP8 and IL6. KEGG signaling pathways: Kaposi sarcoma-associated herpesvirus infection, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, IL-17 signaling pathway and Hepatitis B, etc. |
[53] |
Huashi Baidu formula | TCMSP; GeneCards; Cytoscape; STRING |
Key targets: MAPK3, MAPK8, TP53, CASP3, IL6, TNF, MAPK1, CCL2, PTGS2, etc. KEGG signaling pathways: TNF signaling pathway, PI3K-Akt signaling pathway, NOD-like receptor signaling pathway, MAPK signaling pathway, and HIF-1 signaling pathway. Molecular docking: Baicalein+ACE2; Quercetin+ACE2. |
[54] |
Toujie Quwen granule | TCMSP; Swiss Target Prediction; STRING; R software; Cytoscape |
Key active ingredients: umbelliprenin, quercetin, kaempferol, luteolin, praeruptorin E, stigmasterol, and oroxylin A. Key targets: EGFR, CASP3, STAT3, ESR1, FPR2, F2, BCL2L1, BDKRB2, MPO, and ACE. Signaling pathways: regulation of inflammatory response, viral process, neutrophil mediated immunity, PI3K-Akt signaling pathway, MAPK signaling pathway, Jak-STAT signaling pathway, Complement and coagulation cascades, and HIF-1 signaling pathway. |
[55] |
Ma Xing Shi Gan Decoction | TCMSP; PharmMapper; Swiss Target Prediction; STITCH; Cytoscape; STRING R software |
Key targets: HSP90, AKT1, JUN, MAPK1, TP53, ESR1, VEGFA, and TNF. KEGG signaling pathways: inflammation-related pathways, immunomodulation-related pathways, and viral infection-related pathways. Mechanisms: reducing inflammation, suppressing cytokine storm, protecting pulmonary alveolar-capillary barrier, alleviating pulmonary edema, regulating immune response, and decreasing fever. |
[56] |
Qing-Fei-Pai-Du decoction | UHPLC-Q-Orbitrap HRMS; DrugBank; PubChem; STITCH; ETCM; GTEx; STRING; Cytoscape |
Key active ingredients: baicalin, glycyrrhizic acid, hesperidin, and hyperoside. Key targets: AKT1, TNF-α, IL6, PTGS2, HMOX1, IL10, and TP53. Molecular docking: Baicalin+ HMOX1/ PRKACA/ COMT/ CSNK2B; Ephedrine+ COMT/ PLAT; Hesperidin+ HMOX1; Hyperoside+ HMOX1/ PRKACA/ COMT/ CSNK2B; Isochlorogenic acid A+ HMOX1; Pseudoephedrine+ GLA; Glycyrrhizic acid+ HMOX1. In intro experiments: inhibiting IL6, CCL2, TNF-α, NF-κB, PTGS1/2, CYP1A1, CYP3A4 activity, the up-regulation of IL10 expression, and repressing platelet aggregation. |
[57] |
Lian Hua Qing Wen | TCMSP; ETCM; STRING; Cytoscape |
KEGG signaling pathways: cancer, immune system-, and viral infection diseases. Mechanisms: modulating the inflammatory process, exerting antiviral effects, repairing lung injury, relieving the “cytokine storm” and improving ACE2-expression-disorder-caused symptoms. |
[58] |
Maxingyigan Decoction | TCMSP; STRING; Cytoscape |
Molecular docking: Quercetin/Formononetin/Luteolin+ IL6/ CASP3/ IL4/ SARS-CoV-2. Mechanisms: anti-inflammatory and immunity-based actions involving activation of T cells, lymphocytes, and leukocytes, as well as cytokine-cytokine-receptor interaction, and chemokine signaling pathways. |
[59] |
Cold-Damp Plague Formula | TCMSP; TCMID; Swiss ADME; STITCH; GeneCards; STRING; Cytoscape; |
Key targets: IL6, TNF, IL10, MAPK8, MAPK3, CXCL8, CASP3, PTGS2, TP53, and MAPK1. KEGG signaling pathways: TNF signaling pathway, MAPK signaling pathway, Fc epsilon RI signaling pathway, toxoplasmosis, leishmaniasis, and so on. Molecular docking: Quercetin/Luteolin+IL6; L-tyrosine/L-phenylalanine+ACE2. |
[60] |
Respiratory Detox Shot | TCMSP; TCMID; ETCM; Swiss Target Prediction; SEA; TargetNet; HINT; Cytoscape; CPDB; DAVID; STRING |
Molecular docking: One-hundred and eighteen candidate constituents showed a high binding affinity with SARS-coronavirus-2 3-chymotrypsin-like protease (3CLpro). Key active ingredients in vitro experiments: Luteolin, Licoisoflavone B, Fisetin, Quercetin, Glyasperin F, Isolicoflavonol, Semilicoisoflavone-B. |
[61] |
Rhizoma Polygonati | TCMSP; Swiss Target Prediction; GenCLiP3; NCBI; GeneCard; STRING; DAVID; Cytoscape |
Key active ingredients: diosgenin, 3′-Methoxydaidzein, 4′,5-Dihydroxyflavone, (2R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-one, , DFV, Lopinavir, Remdesivir, (+)-Syringaresinol-O-beta-D-glucoside, beta-sitosterol, sitosterol, baicalein, methylprotodioscin_qt. Key targets: CASP3, TP53, MAPK14, PTGS2, CAT, FOS, PPARG, CASP8, BCL2L1, IL2, RELA. KEGG signaling pathways: tuberculosis, p53 signaling, AGE-RAGE in diabetic complications, IL-17 cytokine, apoptosis, and viral infection. Molecular docking: Diosgenin/ (+)-Syringaresinol-O-beta-D-glucoside+ ACE2/3CL/ Spike protein S1/ RNA-dependent RNA polymerase. |
[62] |
However, the data in TCMCOVID is based on SARS and is not completely consistent with SARS COV2, and the original data used in this database is the result of analysis of mice. Thus, using this tool to verify analysis results has certain limitations. In addition, TCM prescription is a complex system, not simply the accumulation of ingredients, and network pharmacology has limitations. In order to be safe and effective for clinical use, further in vivo and in vitro activity evaluation and pharmacological verification are needed.
5. Conclusion
The preventive and therapeutic effect of SFJD on COVID-19 may contribute in participating in the moderate immune system, anti-inflammatory, anti-virus and other methods through the action of quercetin, luteolin, kaempferol, baicalein and other active ingredients on core targets such as IL-6, IL-10, TNF, etc. Combined with clinical research and network pharmacological analysis, in the early onset of COVID-19, non-infant patients with acute upper respiratory tract infection with heat toxin attacking the lung syndrome, fever, fatigue and other symptoms, timely oral SFJD capsule for a certain course of treatment can reduce or eliminate the patient's clinical symptoms.
Author contributions
Q-WH is the corresponding authors on the study. H-JX and Z-WD are first authors and responsible for collecting materials and writing the paper. G-HL, Q-XG and JW helped in organizing the information and edited the article pictures. All authors read and approved the final manuscript.
Financial support
This work is financially supported by the Xinglin Scholars Talent Promotion Plan of Chengdu University of Traditional Chinese Medicine (Code: QNXZ2018023 and Core: XSGG2019008).
Declaration of Competing Interests
The authors declare that they have no competing interests.
Data availability
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Acknowledgments
We are indebted to our alma mater, Chengdu University of Traditional Chinese Medicine for providing convenience in the collection of documents. Thanks for all the help from everyone in our lab.
Footnotes
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.eujim.2020.101241.
Appendix. Supplementary materials
References
- 1.Funk C. A Snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Front. Pharmacol. 2020;11:937. doi: 10.3389/fphar.2020.00937. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Ciotti, M., et al., The COVID-19 pandemic, critical reviews in clinical laboratory sciences, (2020) 1-24. 10.1080/10408363.2020.1783198.
- 3.Chen H. Chinese medicine for COVID-19: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99:e20660. doi: 10.1097/md.0000000000020660. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Ju, L., et al., Study on application of traditional Chinese medicine in prevention and treatment of novel coronavirus pneumonia, Chinese Herb. Med., 1-5.
- 5.Li Q. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China. Front. Med. 2020 doi: 10.1007/s11684-020-0801-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Zhang, Y., Prevention of COVID-19 with TCM preventive treatment, Chinese medicine information. 37 (2020) 5-8. 10.19656/j.cnki.1002-2406.200031.
- 7.Du H. Traditional Chinese medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP) Chinese J. Nat. Med. 2020;18:206–210. doi: 10.1016/S1875-5364(20)30022-4. 10.1016/s1875-5364(20)30022-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Luo E. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China. Chin Med. 2020;15:34. doi: 10.1186/s13020-020-00317-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Zhang D. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence. Pharmacol. Res. 2020;157 doi: 10.1016/j.phrs.2020.104882. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Zhuang W. Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China. Front. Pharmacol. 2020:11. doi: 10.3389/fphar.2020.01066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ho, L., et al., Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19. 36 (2020) 101116. 10.1016/j.eujim.2020.101116. [DOI] [PMC free article] [PubMed]
- 12.GeneralOfficeoftheNationalHealthCommissionofthePeople'sRepublicofChina Diagnosis and treatment of corona virus disease-19(7th trial edition) Chinese Med. 2020;15:801–805. doi: 10.3760/j.issn.1673-4777.2020.06.001. [DOI] [Google Scholar]
- 13.Chen, L., et al., Clinical Efficacy of Shufeng Jiedu Capsule Combined with Western Medicine in Treatment of Common COVID-19 Patients by Retrospective Analysis, Chinese Journal of Experimental Prescription, (2020) 1-8. 10.13422/j.cnki.syfjx.20201628.
- 14.Xiao Q. Analysis of the value of traditional Chinese medicine Shufeng Jiedu Capsule combined with Arbidol in the treatment of mild new coronavirus pneumonia. Chinese Med. Emergency. 2020;29:756–758. doi: 10.3969/j.issn.1004-745X.2020.05.002. [DOI] [Google Scholar]
- 15.Xiang-kun, Q., et al., Observation on clinical effect of Shufeng Jiedu Capsule combined with Arbidol Hydrochloride Capsule in treatment of COVID-19 Chinese Herbal Medicine. 51 (2020) 1167-1170. 10.7501/j.issn.0253-2670.2020.05.011.
- 16.Han Y. Study on mechanism of anti-inflammation and immunoregulation of Shufeng Jiedu Capsule based on network pharmacology. Chinese Herb. Med. 2019;50:3555–3562. doi: 10.7501/j.issn.0253-2670.2019.15.006. [DOI] [Google Scholar]
- 17.Bao Y. Study on broad-spectrum antiviral effect of Shufeng Jiedu capsules. New Chinese Med. 2019;51:5–8. doi: 10.13457/j.cnki.jncm.2019.12.002. [DOI] [Google Scholar]
- 18.Liu Y. Efficacy of Shufeng Jiedu Capsules in the treatment of sepsis: A prospective, randomized, placebo-controlled trial. Eu. J. Integr. Med. 2020:38. doi: 10.1016/j.eujim.2020.101172. [DOI] [Google Scholar]
- 19.Li S. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chinese J. Nat. Med. 2013;11:110–120. doi: 10.1016/S1875-5364(13)60037-0. 10.1016/s1875-5364(13)60037-0. [DOI] [PubMed] [Google Scholar]
- 20.Kong Q. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. Biomed Pharmacother. 2020;128 doi: 10.1016/j.biopha.2020.110316. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Fei-Fei G. TCMATCOV–a bioinformatics platform to predict efficacy of TCM against COVID-19. China J. Chinese Mater. Med. 2020:45. doi: 10.19540/j.cnki.cjcmm.20200312.401. [DOI] [PubMed] [Google Scholar]
- 22.Zhang C. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int. J. Antimicrob. Agents. 2020;55 doi: 10.1016/j.ijantimicag.2020.105954. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Zhang D. Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU. Clin. Chim. Acta. 2020 doi: 10.1016/j.cca.2020.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Scala S. Fighting the host reaction to SARS-COv-2 in Critically Ill Patients: the possible contribution of off-label drugs. Front. Immunol. 2020;11:1201. doi: 10.3389/fimmu.2020.01201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Song M. Low-Dose IFNγ Induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer. Cancer Res. 2019;79:3737–3748. doi: 10.1158/0008-5472.Can-19-0596. [DOI] [PubMed] [Google Scholar]
- 26.Chen X.-q. Human interleukin-10 mediated nuclear transcription factor P65 reduces ventilator-related lung injury. Strait Pharm. 2019;31:29–32. [Google Scholar]
- 27.Qian Q. Direct evidence of active SARS-CoV-2 replication in the intestine. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Trottein F. Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection. Cell Rep. 2020 doi: 10.1016/j.celrep.2020.107915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Ali N. Liver injury in severe COVID-19 infection: current insights and challenges. Expert Review Gastroenterol. Hepatol. 2020:1–6. doi: 10.1080/17474124.2020.1794812. [DOI] [PubMed] [Google Scholar]
- 30.Gupta A. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020 doi: 10.1038/s41591-020-0968-3. [DOI] [PubMed] [Google Scholar]
- 31.Yang J. Quercetin improves immune function in Arbor Acre broilers through activation of NF-κB signaling pathway. Poult. Sci. 2020;99:906–913. doi: 10.1016/j.psj.2019.12.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Ince E. The protective effect of quercetin in the alcohol-induced liver and lymphoid tissue injuries in newborns. Mol. Biol. Rep. 2020;47:451–459. doi: 10.1007/s11033-019-05148-0. [DOI] [PubMed] [Google Scholar]
- 33.Dong Y. Dietary quercetin alleviated DSS-induced colitis in mice through several possible pathways by transcriptome analysis. Curr. Pharm. Biotechnol. 2020 doi: 10.2174/1389201021666200711152726. [DOI] [PubMed] [Google Scholar]
- 34.Tang S. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomed. Pharmacother. 2020;121 doi: 10.1016/j.biopha.2019.109604. [DOI] [PubMed] [Google Scholar]
- 35.Guo, G., et al., Quercetin supports cell viability and inhibits apoptosis in cardiocytes by down-regulating miR-199a, Artificial cells, nanomedicine, biotechnology. 47 (2019) 2909-2916. 10.1080/21691401.2019.1640711. [DOI] [PubMed]
- 36.Ding X. Luteolin attenuates atherosclerosis via modulating signal transducer and activator of transcription 3-mediated inflammatory response. Drug Design, Develop. Therapy. 2019;13:3899–3911. doi: 10.2147/dddt.S207185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.El-Deeb O. The modulatory effects of luteolin on cyclic AMP/Ciliary neurotrophic factor signaling pathway in experimentally induced autoimmune encephalomyelitis. IUBMB Life. 2019;71:1401–1408. doi: 10.1002/iub.2099. [DOI] [PubMed] [Google Scholar]
- 38.Sekiguchi A. Inhibitory effect of kaempferol on skin fibrosis in systemic sclerosis by the suppression of oxidative stress. J. Dermatol. Sci. 2019;96:8–17. doi: 10.1016/j.jdermsci.2019.08.004. [DOI] [PubMed] [Google Scholar]
- 39.Kalbolandi S. Luteolin confers renoprotection against ischemia-reperfusion injury via involving Nrf2 pathway and regulating miR320. Mol. Biol. Rep. 2019;46:4039–4047. doi: 10.1007/s11033-019-04853-0. [DOI] [PubMed] [Google Scholar]
- 40.Yan H. Luteolin decreases the yield of influenza A virus in vitro by interfering with the coat protein I complex expression. J. Nat. Med. 2019;73:487–496. doi: 10.1007/s11418-019-01287-7. [DOI] [PubMed] [Google Scholar]
- 41.Li Q. Synergistic effect of kaempferol and 5-fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway. Mol. Med. Reports. 2019;20:728–734. doi: 10.3892/mmr.2019.10296. [DOI] [PubMed] [Google Scholar]
- 42.Tsai M. Kaempferol protects against propacetamol-induced acute liver injury through CYP2E1 inactivation, UGT1A1 activation, and attenuation of oxidative stress, inflammation and apoptosis in mice. Toxicol. Lett. 2018;290:97–109. doi: 10.1016/j.toxlet.2018.03.024. [DOI] [PubMed] [Google Scholar]
- 43.Wang H. Kaempferol protects mice from d-GalN/LPS-induced acute liver failure by regulating the ER stress-Grp78-CHOP signaling pathway. Biomed. Pharmacother. 2019;111:468–475. doi: 10.1016/j.biopha.2018.12.105. [DOI] [PubMed] [Google Scholar]
- 44.Rabha D. Kaempferol attenuates acute lung injury in caecal ligation and puncture model of sepsis in mice. Exp. Lung Res. 2018;44:63–78. doi: 10.1080/01902148.2017.1420271. [DOI] [PubMed] [Google Scholar]
- 45.Vishwakarma A. Effect of Kaempferol pretreatment on myocardial injury in rats. Cardiovasc. Toxicol. 2018;18:312–328. doi: 10.1007/s12012-018-9443-5. [DOI] [PubMed] [Google Scholar]
- 46.Meng X. Wogonin protects against cisplatin-induced acute kidney injury by targeting RIPK1-mediated necroptosis. Lab. Invest. J. Tech. Methods Pathol. 2018;98:79–94. doi: 10.1038/labinvest.2017.115. [DOI] [PubMed] [Google Scholar]
- 47.Badawy A. Wogonin pre-treatment attenuates cisplatin-induced nephrotoxicity in rats: impact on PPAR-γ, inflammation, apoptosis and Wnt/β-catenin pathway. Chem. Biol. Interact. 2019;308:137–146. doi: 10.1016/j.cbi.2019.05.029. [DOI] [PubMed] [Google Scholar]
- 48.Du X. Wogonin attenuates liver fibrosis via regulating hepatic stellate cell activation and apoptosis. Int. Immunopharmacol. 2019;75 doi: 10.1016/j.intimp.2019.05.056. [DOI] [PubMed] [Google Scholar]
- 49.Wang C. Inhibition of lung cancer proliferation by wogonin is associated with activation of apoptosis and generation of reactive oxygen species. Balkan Med. J. 2019;37:29–33. doi: 10.4274/balkanmedj.galenos.2019.2019.7.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Tan H. A flavone, Wogonin from Scutellaria baicalensis inhibits the proliferation of human colorectal cancer cells by inducing of autophagy, apoptosis and G2/M cell cycle arrest via modulating the PI3K/AKT and STAT3 signalling pathways. J. B.U.ON. 2019;24:1143–1149. [PubMed] [Google Scholar]
- 51.Fan L. Wogonin suppresses IL-10 production in B Cells via STAT3 and ERK signaling pathway. J. Immunol. Res. 2020 doi: 10.1155/2020/3032425. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Seong R. Wogonin, a flavonoid isolated from Scutellaria baicalensis, has anti-viral activities against influenza infection via modulation of AMPK pathways. Acta Virol. 2018;62:78–85. doi: 10.4149/av_2018_109. [DOI] [PubMed] [Google Scholar]
- 53.Chen X. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) Based on Netw. Pharmacol. 2020;17:2511–2530. doi: 10.7150/ijms.46378. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Tao, Q., et al., Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19. 46 (2020) 1345-1353. 10.1080/03639045.2020.1788070. [DOI] [PMC free article] [PubMed]
- 55.Huang, Y., et al., Therapeutic mechanism of Toujie Quwen granules in COVID-19 based on network pharmacology. 13 (2020) 15. 10.1186/s13040-020-00225-8. [DOI] [PMC free article] [PubMed]
- 56.Wang, Y., et al., Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19. 24 (2020) 3360-3384. 10.26355/eurrev_202003_20704. [DOI] [PubMed]
- 57.Zhao, J., et al., Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19, (2020) 153315. 10.1016/j.phymed.2020.153315. [DOI] [PMC free article] [PubMed]
- 58.Zheng, S., et al., Network pharmacology analysis of the therapeutic mechanisms of the traditional Chinese herbal formula Lian Hua Qing Wen in Corona virus disease 2019 (COVID-19), gives fundamental support to the clinical use of LHQW. 79 (2020) 153336. 10.1016/j.phymed.2020.153336. [DOI] [PMC free article] [PubMed]
- 59.Wang M. Theoretical study of the molecular mechanism of Maxingyigan decoction against COVID-19: Netw. Pharmacol.-Based Strat. 2020 doi: 10.2174/1386207323666200806164635. [DOI] [PubMed] [Google Scholar]
- 60.Han, L., et al., Potential mechanism prediction of Cold-Damp Plague Formula against COVID-19 via network pharmacology analysis and molecular docking. 15 (2020) 78. doi: 10.1186/s13020-020-00360-8. [DOI] [PMC free article] [PubMed]
- 61.Zhang, Z.-j., et al., Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC–MSE analysis. 18. [DOI] [PMC free article] [PubMed]
- 62.Mu, C., et al., Potential compound from herbal food of rhizoma polygonati for treatment of COVID-19 analyzed by network pharmacology and molecular docking technology, (2020) 104149. doi: 10.1016/j.jff.2020.104149. [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.